MX2021010759A - Regimen de dosificacion para un agonista de los receptores de s1p. - Google Patents
Regimen de dosificacion para un agonista de los receptores de s1p.Info
- Publication number
- MX2021010759A MX2021010759A MX2021010759A MX2021010759A MX2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage regimen
- receptor agonist
- dosage
- daily dosage
- regimen
- Prior art date
Links
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los moduladores o agonistas de los receptores de S1P se administran siguiendo un régimen de dosificación en donde, durante los días iniciales del tratamiento, la dosificación diaria es más baja que la dosificación diaria convencional.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13967208P | 2008-12-22 | 2008-12-22 | |
US21853009P | 2009-06-19 | 2009-06-19 | |
US24671509P | 2009-09-29 | 2009-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021010759A true MX2021010759A (es) | 2022-07-19 |
Family
ID=41667217
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011006623A MX2011006623A (es) | 2008-12-22 | 2009-12-21 | Regimen de dosificacion para un agonista de los receptores de s1p. |
MX2021010759A MX2021010759A (es) | 2008-12-22 | 2011-06-17 | Regimen de dosificacion para un agonista de los receptores de s1p. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011006623A MX2011006623A (es) | 2008-12-22 | 2009-12-21 | Regimen de dosificacion para un agonista de los receptores de s1p. |
Country Status (41)
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104800208A (zh) | 2008-03-17 | 2015-07-29 | 埃科特莱茵药品有限公司 | 选择性s1p1受体激动剂的给药方案 |
EP3409274B1 (en) | 2008-12-22 | 2019-11-20 | Novartis AG | Dosage regimen for a s1p receptor agonist |
CA3129729A1 (en) | 2009-09-29 | 2011-04-07 | Novartis Ag | Dosage regimen of an s1p receptor modulator |
US20110124605A1 (en) * | 2009-11-20 | 2011-05-26 | Shreeram Aradhye | Use of an S1P Receptor Agonist |
EP3378854B1 (en) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
EA201201515A1 (ru) * | 2010-05-06 | 2013-08-30 | Новартис Аг | Схема приема производных диарилсульфидов |
EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
FR2968556B1 (fr) | 2010-12-13 | 2013-12-27 | Centre Nat Rech Scient | Inhibiteurs des infections a vih et leurs utilisations |
DK2675893T3 (en) | 2011-02-18 | 2019-04-15 | Scripps Research Inst | Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate |
JO3177B1 (ar) | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
US9592268B2 (en) | 2011-05-23 | 2017-03-14 | Cornell University | Endothelium protective materials and methods of use |
TW201320994A (zh) | 2011-10-11 | 2013-06-01 | Novartis Ag | 投藥療程 |
CN104540800B (zh) | 2012-08-17 | 2017-05-10 | 埃科特莱茵药品有限公司 | 制备(2z,5z)‑5‑(3‑氯‑4‑((r)‑2,3‑二羟基丙氧基)苯亚甲基)‑2‑(丙亚氨基)‑3‑(邻甲苯基)噻唑烷‑4‑酮的方法及在该方法中所用的中间产物 |
US20160129084A1 (en) * | 2013-03-06 | 2016-05-12 | Acorda Therapeutics, Inc. | Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure |
WO2015053879A1 (en) | 2013-10-11 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
WO2015053878A1 (en) | 2013-10-11 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same |
IL305337A (en) * | 2014-04-10 | 2023-10-01 | Novartis Ag | A therapeutic regimen containing an immediate release dose of an S1P modulator |
KR20230147768A (ko) | 2014-12-11 | 2023-10-23 | 액테리온 파마슈티칼 리미티드 | 선택적 s1p1 수용체 효능제에 대한 투약 섭생 |
CA3002540C (en) * | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
AU2016284162A1 (en) | 2015-06-22 | 2018-02-01 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders |
JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
WO2021084068A1 (en) | 2019-10-31 | 2021-05-06 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
WO2021158848A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor agonist |
US11135197B2 (en) | 2020-02-07 | 2021-10-05 | Argentum Pharmaceuticals Llc | Dosage regimen of an S1P receptor modulator |
CN113332435B (zh) * | 2021-06-18 | 2022-10-18 | 广州中医药大学(广州中医药研究院) | 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604229A (en) | 1992-10-21 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
JP2004507552A (ja) | 2000-08-31 | 2004-03-11 | メルク エンド カムパニー インコーポレーテッド | 免疫調節剤としてのリン酸誘導体 |
BR0311173A (pt) | 2002-05-16 | 2005-03-15 | Novartis Ag | Uso de agentes de ligação do receptor de edg em câncer |
JP4861177B2 (ja) * | 2003-09-12 | 2012-01-25 | ニューロノバ エービー | 神経系の障害の処置 |
US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
NZ554720A (en) * | 2004-11-29 | 2011-04-29 | Novartis Ag | Compositions and uses of fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol) |
EP1688141A1 (en) * | 2005-01-31 | 2006-08-09 | elbion AG | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
WO2006085316A2 (en) * | 2005-02-10 | 2006-08-17 | G.I. View Ltd. | Advancement techniques for gastrointestinal tool with guiding element |
SG187458A1 (en) * | 2007-10-12 | 2013-02-28 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
CN104800208A (zh) | 2008-03-17 | 2015-07-29 | 埃科特莱茵药品有限公司 | 选择性s1p1受体激动剂的给药方案 |
EP2303250A1 (en) | 2008-06-20 | 2011-04-06 | Novartis AG | Paediatric compositions for treating1 multiple sclerosis |
JO3044B1 (ar) | 2008-12-22 | 2016-09-05 | Novartis Ag | نظام تناول جرعة لمنبه مستقبل s1p |
EP3409274B1 (en) | 2008-12-22 | 2019-11-20 | Novartis AG | Dosage regimen for a s1p receptor agonist |
-
2009
- 2009-12-21 EP EP18179301.9A patent/EP3409274B1/en active Active
- 2009-12-21 ES ES18179301T patent/ES2760607T3/es active Active
- 2009-12-21 DK DK09797234.3T patent/DK2379067T3/en active
- 2009-12-21 PT PT182010629T patent/PT3453387T/pt unknown
- 2009-12-21 CN CN2009801518640A patent/CN102264359A/zh active Pending
- 2009-12-21 DK DK18201062.9T patent/DK3453387T3/da active
- 2009-12-21 DK DK18179301.9T patent/DK3409274T3/da active
- 2009-12-21 EP EP09797234.3A patent/EP2379067B1/en not_active Revoked
- 2009-12-21 CA CA2747802A patent/CA2747802C/en active Active
- 2009-12-21 SG SG2011037629A patent/SG171404A1/en unknown
- 2009-12-21 AU AU2009330176A patent/AU2009330176C9/en not_active Withdrawn - After Issue
- 2009-12-21 HU HUE18179301A patent/HUE048717T4/hu unknown
- 2009-12-21 EA EA201100978A patent/EA201100978A1/ru unknown
- 2009-12-21 UY UY0001032352A patent/UY32352A/es not_active Application Discontinuation
- 2009-12-21 LT LTEP18201062.9T patent/LT3453387T/lt unknown
- 2009-12-21 TW TW098143960A patent/TW201028143A/zh unknown
- 2009-12-21 AR ARP090105010A patent/AR074826A1/es not_active Application Discontinuation
- 2009-12-21 NZ NZ593065A patent/NZ593065A/xx not_active IP Right Cessation
- 2009-12-21 MX MX2011006623A patent/MX2011006623A/es unknown
- 2009-12-21 US US13/141,552 patent/US20110257133A1/en not_active Abandoned
- 2009-12-21 LT LTEP18179301.9T patent/LT3409274T/lt unknown
- 2009-12-21 BR BRPI0923500-0A patent/BRPI0923500A2/pt not_active Application Discontinuation
- 2009-12-21 EP EP22187007.4A patent/EP4098256A1/en active Pending
- 2009-12-21 EP EP16182876.9A patent/EP3120844A1/en not_active Withdrawn
- 2009-12-21 PT PT97972343T patent/PT2379067E/pt unknown
- 2009-12-21 KR KR1020117017073A patent/KR101347919B1/ko active IP Right Grant
- 2009-12-21 HU HUE18201062A patent/HUE052048T2/hu unknown
- 2009-12-21 ME MEP-2020-156A patent/ME03802B/me unknown
- 2009-12-21 RS RS20200900A patent/RS60666B1/sr unknown
- 2009-12-21 EP EP20160225.7A patent/EP3677260A1/en active Pending
- 2009-12-21 US US12/642,892 patent/US20100160259A1/en not_active Abandoned
- 2009-12-21 PL PL09797234T patent/PL2379067T3/pl unknown
- 2009-12-21 ES ES18201062T patent/ES2810823T3/es active Active
- 2009-12-21 EP EP18201062.9A patent/EP3453387B1/en active Active
- 2009-12-21 MA MA34034A patent/MA32981B1/fr unknown
- 2009-12-21 SI SI200932080T patent/SI3453387T1/sl unknown
- 2009-12-21 WO PCT/US2009/068888 patent/WO2010075239A1/en active Application Filing
- 2009-12-21 SI SI200932015T patent/SI3409274T1/sl unknown
- 2009-12-21 PE PE2011001265A patent/PE20120337A1/es not_active Application Discontinuation
- 2009-12-21 HU HUE09797234A patent/HUE026869T2/en unknown
- 2009-12-21 JP JP2011542521A patent/JP2012513401A/ja not_active Withdrawn
- 2009-12-21 EP EP15158251.7A patent/EP2907511A1/en not_active Withdrawn
- 2009-12-21 RS RS20191546A patent/RS59857B1/sr unknown
- 2009-12-21 PL PL18179301T patent/PL3409274T3/pl unknown
- 2009-12-21 PT PT181793019T patent/PT3409274T/pt unknown
- 2009-12-21 PL PL18201062T patent/PL3453387T3/pl unknown
- 2009-12-21 ME MEP-2019-339A patent/ME03594B/me unknown
- 2009-12-21 ES ES09797234.3T patent/ES2552823T3/es active Active
- 2009-12-21 SI SI200931311T patent/SI2379067T1/sl unknown
-
2011
- 2011-05-25 ZA ZA2011/03863A patent/ZA201103863B/en unknown
- 2011-05-25 CR CR20110274A patent/CR20110274A/es not_active Application Discontinuation
- 2011-05-26 TN TN2011000272A patent/TN2011000272A1/fr unknown
- 2011-05-26 IL IL213170A patent/IL213170A0/en unknown
- 2011-06-17 MX MX2021010759A patent/MX2021010759A/es unknown
- 2011-06-21 CL CL2011001529A patent/CL2011001529A1/es unknown
- 2011-06-22 HN HN2011001759A patent/HN2011001759A/es unknown
- 2011-06-22 CU CU20110136A patent/CU20110136A7/es unknown
- 2011-06-22 EC EC2011011222A patent/ECSP11011222A/es unknown
- 2011-06-23 CO CO11079290A patent/CO6390117A2/es not_active Application Discontinuation
-
2012
- 2012-08-06 ZA ZA2012/05942A patent/ZA201205942B/en unknown
-
2013
- 2013-05-31 CL CL2013001558A patent/CL2013001558A1/es unknown
- 2013-09-06 US US14/020,058 patent/US20140066657A1/en not_active Abandoned
-
2014
- 2014-01-31 US US14/169,660 patent/US20140148415A1/en not_active Abandoned
- 2014-04-10 JP JP2014080892A patent/JP2014144970A/ja not_active Withdrawn
-
2015
- 2015-10-14 JP JP2015202669A patent/JP2016135752A/ja not_active Withdrawn
- 2015-11-06 HR HRP20151190TT patent/HRP20151190T1/hr unknown
- 2015-11-30 CY CY20151101084T patent/CY1116990T1/el unknown
- 2015-12-02 US US14/956,855 patent/US20160081949A1/en not_active Abandoned
-
2016
- 2016-05-23 US US15/161,778 patent/US20160263061A1/en not_active Abandoned
-
2017
- 2017-03-06 JP JP2017041331A patent/JP2017141238A/ja not_active Withdrawn
- 2017-03-21 US US15/465,091 patent/US20170189353A1/en not_active Abandoned
-
2018
- 2018-06-11 US US16/005,137 patent/US20180289638A1/en not_active Abandoned
- 2018-11-26 US US16/199,905 patent/US20190091180A1/en not_active Abandoned
-
2019
- 2019-05-22 JP JP2019095899A patent/JP7329965B2/ja active Active
- 2019-12-02 HR HRP20192175TT patent/HRP20192175T1/hr unknown
- 2019-12-03 CY CY20191101264T patent/CY1122812T1/el unknown
-
2020
- 2020-05-05 US US16/867,293 patent/US20200330407A1/en not_active Abandoned
- 2020-05-18 IL IL274756A patent/IL274756A/en unknown
- 2020-07-27 HR HRP20201167TT patent/HRP20201167T1/hr unknown
- 2020-08-03 CY CY20201100712T patent/CY1123255T1/el unknown
- 2020-11-17 LU LU00183C patent/LUC00183I2/fr unknown
- 2020-11-17 LT LTPA2020005C patent/LTPA2020005I1/lt unknown
- 2020-11-18 NO NO2020038C patent/NO2020038I1/no unknown
- 2020-11-19 FR FR20C1060C patent/FR20C1060I1/fr active Active
- 2020-11-19 HU HUS2000046C patent/HUS2000046I1/hu unknown
- 2020-11-19 CY CY2020036C patent/CY2020036I2/el unknown
- 2020-11-23 IL IL278914A patent/IL278914A/en unknown
-
2021
- 2021-09-20 US US17/479,649 patent/US20220142949A1/en active Pending
-
2022
- 2022-04-21 JP JP2022070231A patent/JP2022103194A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021010759A (es) | Regimen de dosificacion para un agonista de los receptores de s1p. | |
MX2011006625A (es) | Regimen de dosificacion de un agonista de los receptores de s1p. | |
PH12017501495A1 (en) | Dosage regimen of an s1p receptor modulator | |
MX2009006304A (es) | Nuevos compuestos de oxadiazol. | |
MX2012000704A (es) | Agonistas de gpr119. | |
EA201491607A1 (ru) | Модуляторы толлподобных рецепторов | |
CL2008002129A1 (es) | Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer. | |
MX341025B (es) | Terapia de combinacion. | |
EA201170198A1 (ru) | Фармацевтические композиции, содержащие лиганды рецептора дофамина | |
MX2011013437A (es) | Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos. | |
GB0812642D0 (en) | Compounds | |
MX2007010752A (es) | Usos oftalmicos de moduladores de receptor s1p. | |
CL2009002017A1 (es) | Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria. | |
JO2730B1 (en) | Medications for the treatment of endometriosis | |
JO2979B1 (en) | Cyclopropyl compounds | |
CU20130155A7 (es) | Régimen de dosificación para un agonista de los receptores de s1p | |
UA106219C2 (ru) | Модуляторы толл-подобных рецепторов | |
CL2010000497A1 (es) | Uso de compuestos derivados de indol para el tratamiento del dolor visceral; compuestos específicos derivados de indol; procedimiento de preparación de un compuesto; composición farmacéutica y uso para el tratamiento de una condición causada por la acción de nos. | |
UA105483C2 (uk) | Похідні ізохінолінону, композиція на їх основі та застосування як інгібіторів рі3k |